Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guangzhou Yidai Pharmaceutical Co. Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is handled by a distinct examiner, JONES, DAMERON LEVEST, within a distinct art unit. The prosecution profile is currently limited to this active matter.
JONES, DAMERON LEVEST is the busiest examiner with 1 pending case, which is the only pending office action for the company. Because the workload is restricted to the distinct art unit, the applicant can focus exclusively on the examiner's specific feedback. This case defines the current relationship between the company and the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17908262 | NON-ANTIBODY BINDING PEPTIDES AND THEIR ANALOGS DUAL-TARGETING TO PD-1 AND PD-L1, AND USES THEREOF | JONES, DAMERON LEVEST | 39d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17908262 | NON-ANTIBODY BINDING PEPTIDES AND THEIR ANALOGS DUAL-TARGETING TO PD-1 AND PD-L1, AND USES THEREOF | JONES, DAMERON LEVEST | 1618 | §112 | Non-Final OA | 39d | Pending | Aug 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial